Navigation Links
Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
Date:5/4/2011

SOUTH SAN FRANCISCO, Calif., May 4, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the first quarter 2011. Onyx reported a non-GAAP net loss of $14.2 million, or $0.23 per diluted share, for the first quarter 2011 compared to a non-GAAP net loss of $1.5 million, or $0.02 per diluted share, for the same period in 2010. Non-GAAP net loss excludes, among other items, adjustments to contingent consideration expense in connection with Onyx's acquisition of Proteolix Inc., or Proteolix; employee stock-based compensation expense; non-cash imputed interest expense related to the application of Accounting Standards Codification ("ASC") 470-20 and charges associated with the restructuring of Onyx's development, collaboration, option and license agreement with S*BIO Pte Ltd., or S*BIO.

"2011 is a pivotal year of execution and growth for Onyx as we prepare to deliver a number of significant near-term milestones," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "The NDA for carfilzomib in relapsed and refractory multiple myeloma is on track for filing; our Phase 3 confirmatory trials, ASPIRE and FOCUS, are enrolling patients; and ONX 0912, our next generation proteasome inhibitor, is expected to advance to Phase 2. Importantly, we are ramping up our preparation for the commercialization of carfilzomib, in anticipation of a potential U.S. launch next year."

On a GAAP basis, Onyx reported a net loss of $49.2 million, or $0.78 per diluted share, for the first quarter 2011 compared to a net loss of $12.0 million, or $0.19 per diluted share, for the same period in 2010. A description of the non-GAAP calculations and reconciliation to comparable GAAP measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Loss."

Revenue from Collaboration Agreement
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... VIEJO, Calif. , Nov. 26, 2014 /PRNewswire/ ... announced that the U.S. Food and Drug Administration ... its New Drug Application (NDA) for AVP-825. AVP-825 ... low-dose sumatriptan powder delivered intranasally utilizing a novel ... the Complete Response letter, and consistent with the ...
(Date:11/26/2014)...  BioScrip ® , Inc. (NASDAQ: BIOS ) announced ... Officer, will present at the Bank of America Merrill Lynch 2014 ... Date: , , , Wednesday, December 3, 2014 , , ... , , , Location: , , , Boca Raton Resort and ... BioScrip, Inc. is a leading national provider ...
(Date:11/26/2014)... , Nov. 26, 2014  Aridis Pharmaceuticals, Inc., ... novel therapies for infectious diseases, announced today the ... internationally recognized key opinion leader in the areas ... advisory board. Founder and Chief Executive ... believe Dr. Opal,s extensive experience investigating bacterial toxins ...
Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... According to the American,Academy of Dermatology (AAD), ... an inflamed skin condition characterized by red, scaly,and ... which tend to,flare up in the winter months, ... Eczema Care Moisturizing Cream and Body Wash, formulated,with ...
... Infection Control, WASHINGTON, Jan. 10 To ... minimize risks during times,of health crisis, DuPont (NYSE: ... its,healthcare products, DuPont(TM) Corian(R) solid surface, has been ... department. The product,recently was incorporated into a children,s ...
Cached Medicine Technology:New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 3DuPont Provides Technology for Washington Hospital Center's Emergency Department 4
(Date:11/27/2014)... HealthDay Reporter WEDNESDAY, Nov. 26, 2014 ... safe and produces an immune system response that could protect ... results reported by the U.S. National Institutes of Health. ... vaccine paves the way for field-testing it in the Ebola-stricken ... as January, said Dr. Anthony Fauci, director of the NIH,s ...
(Date:11/27/2014)... NY (PRWEB) November 27, 2014 The founders ... offering stylish, comfortable and high functioning compression socks, are proud ... newly-released socks use an innovative Gradient Pressure (TM) knitting technology ... blood. , VIM & VIGR’s commitment to adding flair and ... as just functional recently caught the eye of a writer ...
(Date:11/27/2014)... November 27, 2014 Tylenol lawsuits ( ... allegedly injured by the medication are continuing to move ... is looking ahead to a status conference in December, ... Scheduling Order issued earlier this year, a conference in ... at 10:00 a.m. Items likely to be discussed at ...
(Date:11/27/2014)... 2014 “Wekho” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers ... , An interesting new way to travel and experience the ... It’s called Wekho and it’s a free geolocation app ...
(Date:11/27/2014)... 2014 Dr. Ronald Receveur, who has a ... few oral health tips before patients dig into the annual ... New Albany affordable cosmetic dentistry, and his staff ... and sugar. While the staff wishes everyone a happy and ... how patients can enjoy a feast that is also healthy ...
Breaking Medicine News(10 mins):Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4
... The acquisition of Baptist Memorial Hospital in Forrest City, ... Systems. The acute health care centre which is 118-bedded ... Ark.). // ,In addition, some other assets would ... care center (Memphis-based Baptist Memorial Health Care Corp.) The ...
... new online application system for junior doctor posts is not ... the job prospects of many top students. This was the ... system being followed is the “Modernising Medical Careers system” which ... answers. ,The reason for this attack as claimed ...
... Scientists at the U.S. Department of Energy’s Brookhaven ... identifying the many species of microorganisms. They have ... of Applied Environmental Microbiology. Microbiology has many applications ... species useful for cleaning up contamination, to identify ...
... and weight loss failure turned to an online competition to ... a 4 month period.//, ,The competition hosted on WeightLossWars.com ... 25 miles, with the winner of the competition losing 9% ... Jen sending out invitations through WeightLossWars.com to her family and ...
... in matters of sleep till late the reason being ... ray of new light comes the IST project 'Sensation' ... different // countries, addressing sensing of physiological parameters, core ... a multipurpose sensing platform consisting of 17 micro sensors ...
... the protective clothing to astronauts going to space and ... the basis to design// protective clothing for fire fighters ... heat and dangerous circumstances. ,This project nicknamed ... that encompasses an inbuilt cooling system, with a technology ...
Cached Medicine News:Health News:Online recruitment criticised by doctors 2Health News:The Novel Cut and Splice Method Is Used To Recognize Different Microbes 2Health News:Sleep Science awakens from deep slumber! 2
Batch Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 40 tests....
For use with catalog #0540....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Detection of Lupus Anticoagulants. Freeze-dried hexagonal phase phos-phatidylethanolamine; normal plasma with heparin inhibitor; PTT-LS reagent of cephalin and particulate siliceous activator;all fre...
Medicine Products: